Ireland, Belgium And The Netherlands Withdraw From Libmeldy Gene Therapy Pricing Talks
Executive Summary
The BeNeLuxA medicines access coalition has terminated pricing talks with Orchard over its gene therapy Libmeldy.
You may also be interested in...
New Data Means Successful Joint Pricing Talks For Orchard’s Libmeldy in Europe
Orchard Therapeutics has secured reimbursement in Ireland, the Netherlands and Belgium nearly a year after the collapse of joint pricing talks between the company and the three countries.
Hemgenix: European Countries Start Joint HTA Of Another Costly Gene Therapy
CSL’s Hemgenix is the latest expensive gene therapy to come under scrutiny from the BeNeLuxA cross-country coalition.
Cell And Gene Therapy Companies Fear More Market Delays From EU’s Single Review Plans
Biopharma fears that the Joint Clinical Assessment, a first step to harmonizing health technology assessments in the EU, is not fit for purpose for cell and gene therapies and will increase rather than eliminate market access delays.